Orchestra BioMed Announces AVIM Therapy Program Presentations at ICI Meeting
Orchestra BioMed to Participate in the Piper Sandler 36th Annual Healthcare Conference
Orchestra BioMed Holdings, Inc. (NASDAQ: OBIO) had its "buy" rating re-affirmed by analysts at HC Wainwright. They now have a $14.00 price target on the stock.
Orchestra BioMed Holdings Third Quarter 2024 Earnings: Beats Expectations [Yahoo! Finance]
We Think Orchestra BioMed Holdings (NASDAQ:OBIO) Needs To Drive Business Growth Carefully [Yahoo! Finance]